HCPLive Network

Obama Signs Bill to Encourage Schools to Stock Epinephrine

THURSDAY, Nov. 14 (HealthDay News) -- A new law meant to increase the availability of life-saving epinephrine in US schools was signed Wednesday by President Barack Obama.

Epinephrine can help prevent severe reactions (anaphylaxis) and death in children with severe food allergies. The law provides a financial incentive to states to maintain a supply of epinephrine in their schools and to permit trained school staff to administer it, the Wall Street Journal reported.

Only four states -- Maryland, Nebraska, Nevada, and Virginia -- currently require schools to stock epinephrine, according to the Food Allergy Research & Education organization. Another 20 states permit schools to stock the medication but don't require they do so.

"This is something that will save children's lives," Obama said at a ceremony to sign the bill, WSJ reported.

Full Article

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
A new report provides guidance on managing food allergies at school and on the prevention and treatment of food-induced anaphylaxis.
Many children who are initially successfully treated for allergy to cow's milk by oral immunotherapy lose tolerance several years later.
The delay of solid foods until at least 17 weeks of age and continued breastfeeding when cow's milk protein is introduced to infants' diets correlate with a reduced likelihood of food allergies, according to a study published online Nov. 18 in Pediatrics.
Children with a history of severe egg allergy, even anaphylaxis, can safely receive a single dose of trivalent seasonal influenza vaccine, according to a study published in the December issue of the Annals of Allergy, Asthma & Immunology.
Oralair has been approved by the U.S. Food and Drug Administration as the first sublingual treatment for certain grass allergies.
Antibiotics prescribed in doctors' offices are linked with a majority of Clostridium difficile (C. difficile) infection cases in children, according to a new study published online March 3 in the Pediatrics.
Grastek is the first sublingual allergy immunotherapy product to be approved for use in children as young as age 5.
More Reading